<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04225390</url>
  </required_header>
  <id_info>
    <org_study_id>PROMIT</org_study_id>
    <nct_id>NCT04225390</nct_id>
  </id_info>
  <brief_title>Preconditioning of Tumor, Tumor Microenvironment and the Immune System to Immunotherapy</brief_title>
  <acronym>PROMIT</acronym>
  <official_title>A Phase 2, Single Arm Study on Dacarbazine (DTIC) Followed by Immunotherapy Re-challenge in Unresectable or Metastatic Melanoma With Primary Resistance to PD-1/PD-L1 or PD-1 + CTLA-4 Blockade</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Erlangen-Nürnberg Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Regensburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuerzburg University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Erlangen-Nürnberg Medical School</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      PROMIT is a single arm phase 2 trial evaluating the clinical activity of immune checkpoint
      blockade (ICB) after administration of dacarbazine (DTIC) in patients with unresectable or
      metastatic, BRAF wildtype melanoma with primary resistance to anti-programmed-cell-death-1
      (PD-1/PD-L1) or PD-1 plus anti-cytotoxic-T-lymphocyte antigen 4 (CTLA-4) blockade therapy. If
      the activity is clinically meaningful, DTIC could become a new therapeutic option to break
      primary resistance to immunotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROMIT is a phase 2, single arm, open label study of DTIC followed by combined immune
      checkpoint blockade (ICB) therapy or PD-1/PD-L1-blockade monotherapy in adult (≥ 18 years)
      subjects with previously treated, unresectable or metastatic melanoma (Stage III or Stage IV
      melanoma as per the AJCC staging system). Subjects must be BRAF wildtype and must have shown
      primary resistance to ICB. Fresh tumor tissue from an unresectable or metastatic site of
      disease must be available.

      Subjects will be treated with DTIC 850 mg/m² day 1 and 21 i.v. (DTIC phase). Afterwards,
      patients will receive combined ipilimumab (3 mg/kg) and nivolumab (1 mg/kg) 4 times every 3
      weeks i.v. OR nivolumab 240 mg every 2 weeks OR pembrolizumab 200 mg every 3 weeks (ICB
      re-exposure phase; EMA-approved dosing scheme). By the end of the ICB phase, response will be
      documented (primary endpoint). A safety follow-up for treatment-related adverse events will
      be performed until 30 days after the last dose of combined ICB. Patients will be followed for
      survival every 12 weeks after the end of the combined ICB phase (second primary endpoint).
      Tumor and blood samples will be assessed over the course of the study to evaluate changes in
      tumor, tumor microenvironment and immune system.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2020</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of participents with CR, PR, SD or PD</measure>
    <time_frame>week 14</time_frame>
    <description>A patient is defined as responder if a complete response (CR) or partial response (PR) can be seen. A patient with stable disease (SD) or progressive disease (PD) will be defined as non-responder.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Overall survival (OS), defined as the time between study inclusion and date of death (any cause). For subjects without documentation of death, OS will be censored on the last date the subject was known to be alive. OS will be followed continuously while subjects are on the study drug and every 12 weeks via phone contact after subjects discontinue the treatment phase.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Immunotherapy</condition>
  <arm_group>
    <arm_group_label>Dacarbazine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dacarbazine (day1 and day21) 850 mg/m² i.v. followed by re-exposure to the previous immunotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dacarbazine (DTIC)</intervention_name>
    <description>Dacarbazine powder for IV solution</description>
    <arm_group_label>Dacarbazine</arm_group_label>
    <other_name>DTIC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed metastatic melanoma

          2. Progression after checkpoint inhibitor therapy (PD-1/PD-L1 or PD-1 + CTLA-4 blockade)

          3. Accessible tumor metastases

          4. ECOG 0 or 1

          5. Adequate organ function

        Exclusion Criteria:

          1. Uvea melanoma, mucosal melanoma

          2. Previous chemotherapy in metastatic disease

          3. Previous response to checkpoint inhibitor therapy (PD-1/PD-L1 or PD-1 + CTLA-4
             blockade) in metastatic disease

          4. BRAF V600 mutation

          5. Active brain metastases

          6. Autoimmune disease requiring more than 10 mg prednisolone daily or other
             immunosuppressive drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lucie Heinzerling, Prof. Dr. MPH</last_name>
    <phone>+49 (0) 9131- 85 45 804</phone>
    <email>lucie.heinzerling@uk-erlangen.de</email>
  </overall_contact>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 3, 2020</study_first_submitted>
  <study_first_submitted_qc>January 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2020</study_first_posted>
  <last_update_submitted>January 8, 2020</last_update_submitted>
  <last_update_submitted_qc>January 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>immune checkpoint blockade</keyword>
  <keyword>resistance</keyword>
  <keyword>dacarbazine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dacarbazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

